“…To develop a prediction model for risk of revisit, chronic commodities, variables associated with ED revisits, and group of drugs involved in the first episode were included 9,10 : age >80 years, sex, comorbidities (including substance dependence, hypertension, type II diabetes, congestive heart failure [New York Heart Association (NYHA) class II, III, or IV], chronic renal failure [defined in the admission report as grade III to V renal failure based on the National Kidney Foundation guidelines], 11 chronic obstructive pulmonary disease [COPD], atrial fibrillation, dyslipidemia, ischemic heart disease, dementia), the outcome of the patient at discharge, polypharmacy on admission (defined as long-term treatment with more than 5 drugs), 12 high anticholinergic burden from the chronic treatment prescribed (defined as a score of one point or higher according to the Anticholinergic Burden Index scale), 13 visit to an ED in the preceding 3 months, type of DRP (indication, effectiveness, or safety), and therapeutic group involved in the DRP episode.…”